Arcus Biosciences, Inc. (NYSE:RCUS) Holdings Boosted by XTX Topco Ltd

XTX Topco Ltd increased its stake in Arcus Biosciences, Inc. (NYSE:RCUS) by 64.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,434 shares of the company’s stock after purchasing an additional 7,239 shares during the period. XTX Topco Ltd’s holdings in Arcus Biosciences were worth $274,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in RCUS. Barclays PLC lifted its position in Arcus Biosciences by 49.0% in the 3rd quarter. Barclays PLC now owns 118,693 shares of the company’s stock valued at $1,816,000 after purchasing an additional 39,015 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Arcus Biosciences by 2.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock valued at $668,000 after buying an additional 1,117 shares during the period. Nordea Investment Management AB lifted its stake in shares of Arcus Biosciences by 2.5% in the 4th quarter. Nordea Investment Management AB now owns 218,930 shares of the company’s stock worth $3,245,000 after acquiring an additional 5,246 shares during the period. R Squared Ltd bought a new position in shares of Arcus Biosciences in the fourth quarter valued at approximately $26,000. Finally, Principal Financial Group Inc. raised its holdings in Arcus Biosciences by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 263,517 shares of the company’s stock worth $3,924,000 after purchasing an additional 7,906 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

RCUS has been the topic of a number of research reports. Bank of America dropped their price objective on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Morgan Stanley reduced their price objective on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. Finally, Barclays dropped their target price on shares of Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Arcus Biosciences presently has an average rating of “Buy” and a consensus target price of $28.38.

Insider Activity

In other news, CEO Terry J. Rosen acquired 19,800 shares of Arcus Biosciences stock in a transaction dated Thursday, February 27th. The stock was acquired at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the purchase, the chief executive officer now owns 2,554,160 shares of the company’s stock, valued at $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Yasunori Kaneko purchased 20,000 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were purchased at an average price of $10.06 per share, with a total value of $201,200.00. Following the completion of the acquisition, the director now directly owns 28,400 shares of the company’s stock, valued at approximately $285,704. This trade represents a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by insiders.

Arcus Biosciences Trading Down 1.3 %

Shares of NYSE:RCUS opened at $8.30 on Friday. Arcus Biosciences, Inc. has a 12-month low of $6.50 and a 12-month high of $18.98. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $872.65 million, a P/E ratio of -2.63 and a beta of 1.54. The firm has a fifty day moving average of $8.79 and a two-hundred day moving average of $13.07.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $36.00 million for the quarter, compared to analyst estimates of $29.38 million. On average, equities analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.